Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
Overview
Semaglutide is a GLP-1 receptor agonist approved by the FDA under several brand names: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for chronic weight management and cardiovascular-risk reduction. It has one of the largest clinical trial programs of any peptide-derived drug, spanning cardiovascular, renal and metabolic outcome studies. As with every approved molecule on this list, approval covers specific branded products and indications, not research-grade material.
Key research
- Ozempic FDA approval history First approved December 2017 for type 2 diabetes.
- Wegovy FDA approval history Approved June 2021 for chronic weight management.
Last reviewed: September 2026
*Approval refers to specific pharmaceutical products, formulations, jurisdictions and indications containing this molecule. It does not indicate that the Vital Edge Science research product is approved.
